Peripheral Arterial DiseasePhase 1/2NCT00424866
FGF-1 for Intramuscular Injection for the Treatment of Peripheral Arterial Disease
A Phase 1/2 study testing FGF-1 in people with Peripheral Arterial Disease and Stenosis, run by Venturis Therapeutics, Inc. at 1 site in United States.
Trial summary
FGF-1 for the treatment of patients with peripheral arterial disease with intermittent claudication. Read more about this study
- Who is it for?
- Ages 50 to 75 years
- Conditions the study is for
- Peripheral Arterial Disease, Stenosis, Intermittent Claudication
- What is being tested?
- FGF-1
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 24 participants
- Where
- 1 siteUnited States
- Study dates
- 15 Oct 2028to 15 Dec 2030
- Phase
- Phase 1/2
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 50 to 75 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Subjects considered eligible to enter the study must sign an informed consent form prior to the initiation of any study procedures. In the event that the subject must be withdrawn and is re-screened for study participation at a later date, a new informed consent form must be signed. Subjects must be competent to give written informed consent.
- Age must be ≥50 and ≤75 years of age with a life expectancy of > 1 year and leg survival > 6 months. Patients >75 and ≤80 years of age will be considered if they show no signs of cognitive or muscle function decline and are fully able to comply with the protocol.
- Patients must have experienced intermittent claudication for at least 6 months and have been stable for the past 3 months.
- Patients must have peripheral arterial disease, as confirmed by a resting ABI ≥0.40 and <0.90 based on at least one leg as measured using both the dorsal pedis and posterior tibial arteries.
- Stenosis of >70% up to total occlusion must be present in the popliteal artery and/or in the tibial peroneal trunk or at least 2 tibial arteries above the ankle without inflow limitation of the popliteal artery. Adequate popliteal inflow is defined as continuous flow from the abdominal aorta, iliac, common femoral and superficial femoral with any stenosis < 50% as determined either by intra-arterial DSA, CTA or Gd CE-MRA.
- The screening Gardner treadmill test peak walking times (PWT) must be >1 minute and < 12 minutes and limited by pain in one or both calves.
- Preexisting medication regime must be stable for 6 weeks preceding dosing.
Who cannot join
- Evidence of critical leg ischemia, i.e. ischemic rest pain or ischemic ulceration
- Treadmill walking limited by conditions other than intermittent claudication including arthritis, angina and dyspnea
- Lower limb amputation of, or in, either leg including toes
- Evidence of limb ischemia from immunologic or inflammatory disorders
- Leg surgery or revascularization within past 6 months or peripheral angioplasty within past 3 months or anticipated during study
- Participation in any investigational device or drug trial within the past 6 months
Show all 30Show fewer
- Myocardial infarction, unstable angina, stroke or ischemic attack within past 6 months
- New York Heart Association (NYHA) class II, III or IV heart failure, restrictive or hypertrophic cardiomyopathy or severe valvular disease
- QTc elongation greater than 450 ms in males or 460 ms in females
- PT (INR), PTT, urinalysis, thyroid function (T3, T4, TSH) outside normal limits
- Hemorrhage or thrombotic events (e.g. deep vein thrombosis) within past 6 months
- Thrombocytopenia (<100,000/µl), history of heparin-induced thrombocytopenia
- Major surgery with the past 6 months
- Positive proliferative retinopathy exam
- Present of any type of cancer or history of cancer except past (but not present) basal cell dermal carcinoma not on either leg
- Inflammatory or progressive fibrotic or myelofibrotic disorders
- Patients experiencing bacterial or viral infection (e.g. hepatitis or HIV) or who may otherwise be febrile
- Hemoglobin A1c(HgbA1c) of >8%
- Type I diabetes
- Total fasting cholesterol >200
- Uncontrolled hypertension (≥160 systolic or ≥100 diastolic pressure) or hypotension (<90 systolic or <60 diastolic pressure)
- Disease or drug (e.g. systemic corticosteroid) immuno-compromised
- Hepatic dysfunction as defined either by AST or ALT > 2.0 times the upper limit of normal
- Serum creatinine of ≥ 2.5 mg/dl
- Proteinuria (urine protein/creatinine ratio > 3)
- Antiproliferative drugs (e.g. thalidomide, hydroxyurea)
- Radiation therapy
- Implanted devices not compatible with strong magnetic fields
- Life expectance of less than 1 year
- Females who are premenopausal and not sterilized or using adequate birth control or are either pregnant, intend to become pregnant or are nursing
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
About this study
Official title: A Phase 1, Open Label, Dose Response, Pilot Study to Evaluate the Safety and Tolerability of Human Fibroblast Growth Factor-1 (FGF-1) in Peripheral Arterial Disease Patients With Intermittent Claudication
FGF-1 for the treatment of patients with peripheral arterial disease with intermittent claudication.
Read the detailed description
FGF-1 administered by intramuscular injection for the treatment of peripheral arterial disease with intermittent claudication. Eligible patients are allocated to one of three treatment arms. Patients within each dosing group will be randomized between study drug and vehicle control. Safety, pharmacokinetics, and cardiovascular improvement will be evaluated at day 1 and weeks 1, 4 and 12 post dosing.
- Being tested
- FGF-1, Placebo
- Keywords
- Peripheral Arterial Disease, Ischemia, Intermittent Claudication
- Medical subject headings
- Peripheral Arterial Disease, Constriction, Pathologic, Intermittent Claudication, Ischemia
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
FGF-1Drug
Also called Acidic FGF
Doses of FGF-1: 3 ug/kg; 10 ug/kg; 30 ug/kg
Low dose: 3.0 μg/kg Mid dose: 10 μg/kg High dose: 30 µg/kg
PlaceboDrug
Vehicle: 0 µg/kg
| Study group | Role | What they receive |
|---|---|---|
| Placebo | Placebo comparator | The dosing groups correspond to total doses of 0 µg/kg of FGF-1. Receives: Drug: Placebo |
| Human FGF-1 | Active comparator | The dosing groups correspond to total doses of either 3, 10 or 30 µg/kg of FGF-1. Receives: Drug: FGF-1 |
What is being measured
The primary outcome is the main question the study is designed to answer.
Number of participants with adverse events as a measure of safety and tolerability of i.m. injected Cardio Vascu Grow TM, a recombinant Human Fibroblast Growth Factor-1 (FGF-1-141)
Treatment-emergent adverse events (TEAEs) and serious adverse events (TESAEs)
Measured: From enrollment through study completion, an average of 12 weeks
Change from baseline in safety laboratory measurements at 12 weeks
Safety laboratory evaluations on hematology, serum chemistry, and urinalysis
Measured: From enrollment through study completion, an average of 12 weeks
Secondary outcomes (1)
Plasma FGF-1 (1-141) pharmacokinetic measurements at pre-dose, 5, 15, and 30 minutes and at 1, 2, 4, 6, 10, and 24 hours
Pharmacokinetic plasma concentrations of FGF-1 (1-141)
Measured: From enrollment through study completion, an average of 12 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted22 Jan 2007 (estimated)
- Study start15 Oct 2028 (estimated)
- Primary completion5 Feb 2030 (estimated)
- Study completion15 Dec 2030 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Peripheral Arterial DiseaseStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1/2
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 24 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Venturis Therapeutics, Inc.
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00424866
- Sponsor's protocol ID
- CVBT-2006-PAD-01
- Status last verified
- Aug 2026
- First submitted
- 18 Jan 2007
- Last updated
- 19 Aug 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 19 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Phase 1, Open Label, Dose Response, Pilot Study to Evaluate the Safety and Tolerability of Human Fibroblast Growth Factor-1 (FGF-1) in Peripheral Arterial Disease Patients With Intermittent Claudication
- ClinicalTrials.gov ID
- NCT00424866
- Acronym / sponsor ID
- CVBT-2006-PAD-01
- Keywords
- Peripheral Arterial Disease, Ischemia, Intermittent Claudication
- Phase
- Phase 1/2
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 24 participants (estimated)
- Lead sponsor
- Venturis Therapeutics, Inc.Industry (pharma, biotech, devices)
- Study start
- 15 Oct 2028 (estimated)
- Primary completion
- 5 Feb 2030 (estimated)
- Study completion
- 15 Dec 2030 (estimated)
- First posted
- 22 Jan 2007 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
FGF-1 for the treatment of patients with peripheral arterial disease with intermittent claudication.
Detailed description
FGF-1 administered by intramuscular injection for the treatment of peripheral arterial disease with intermittent claudication. Eligible patients are allocated to one of three treatment arms. Patients within each dosing group will be randomized between study drug and vehicle control. Safety, pharmacokinetics, and cardiovascular improvement will be evaluated at day 1 and weeks 1, 4 and 12 post dosing.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Placebo | Placebo comparator | Drug: PlaceboThe dosing groups correspond to total doses of 0 µg/kg of FGF-1. |
| Human FGF-1 | Active comparator | Drug: FGF-1The dosing groups correspond to total doses of either 3, 10 or 30 µg/kg of FGF-1. |
Who may qualify
- Ages
- 50 to 75 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (7 listed)
- Subjects considered eligible to enter the study must sign an informed consent form prior to the initiation of any study procedures. In the event that the subject must be withdrawn and is re-screened for study participation at a later date, a new informed consent form must be signed. Subjects must be competent to give written informed consent.
- Age must be ≥50 and ≤75 years of age with a life expectancy of > 1 year and leg survival > 6 months. Patients >75 and ≤80 years of age will be considered if they show no signs of cognitive or muscle function decline and are fully able to comply with the protocol.
- Patients must have experienced intermittent claudication for at least 6 months and have been stable for the past 3 months.
- Patients must have peripheral arterial disease, as confirmed by a resting ABI ≥0.40 and <0.90 based on at least one leg as measured using both the dorsal pedis and posterior tibial arteries.
- Stenosis of >70% up to total occlusion must be present in the popliteal artery and/or in the tibial peroneal trunk or at least 2 tibial arteries above the ankle without inflow limitation of the popliteal artery. Adequate popliteal inflow is defined as continuous flow from the abdominal aorta, iliac, common femoral and superficial femoral with any stenosis < 50% as determined either by intra-arterial DSA, CTA or Gd CE-MRA.
Key exclusion criteria (30 listed)
- Evidence of critical leg ischemia, i.e. ischemic rest pain or ischemic ulceration
- Treadmill walking limited by conditions other than intermittent claudication including arthritis, angina and dyspnea
- Lower limb amputation of, or in, either leg including toes
- Evidence of limb ischemia from immunologic or inflammatory disorders
- Leg surgery or revascularization within past 6 months or peripheral angioplasty within past 3 months or anticipated during study
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| FGF-1Also: Acidic FGFDoses of FGF-1: 3 ug/kg; 10 ug/kg; 30 ug/kg Low dose: 3.0 μg/kg Mid dose: 10 μg/kg High dose: 30 µg/kg | Drug | Human FGF-1 |
| PlaceboVehicle: 0 µg/kg | Drug | Placebo |
Primary outcome
Number of participants with adverse events as a measure of safety and tolerability of i.m. injected Cardio Vascu Grow TM, a recombinant Human Fibroblast Growth Factor-1 (FGF-1-141)
Time frame: From enrollment through study completion, an average of 12 weeks
Treatment-emergent adverse events (TEAEs) and serious adverse events (TESAEs)
Change from baseline in safety laboratory measurements at 12 weeks
Time frame: From enrollment through study completion, an average of 12 weeks
Safety laboratory evaluations on hematology, serum chemistry, and urinalysis
1 secondary outcome
Plasma FGF-1 (1-141) pharmacokinetic measurements at pre-dose, 5, 15, and 30 minutes and at 1, 2, 4, 6, 10, and 24 hours
Time frame: From enrollment through study completion, an average of 12 weeks
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 19 Aug 2026.
- Related InfoLink provided by the sponsor.
Related trials for Peripheral Arterial Disease
Active, not recruiting
SUCCESS (SelUtion, Safety, effiCaCy, hEalth economicS and promS) PTA Study
Peripheral Artery Disease
RecruitingPhase 3
Reducing Adverse Vascular Outcomes With Factor XI Inhibition in Adult Participants With Peripheral Artery Disease
Peripheral Artery Disease (PAD)
Recruiting
The THOR IDE Study
Peripheral Artery Disease, Peripheral Artery Stenosis
Not yet recruiting
Daily Stretching to Improve Walking in Older Patients With Peripheral Artery Disease: The STRETCH PAD Study
Peripheral Artery Disease (PAD), Intermittent Claudication
Recruiting
WIN Ratio Analysis to Determine a Strategy of Non- Invasive SUpport for Respiratory Failure in the EmeRgency Department
Acute Hypoxic Respiratory Failure, Acute Respiratory Distress Syndrome (ARDS)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1/2 study testing FGF-1 in people with Peripheral Arterial Disease and Stenosis, run by Venturis Therapeutics, Inc. at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 30 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 19 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this combined phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Laurence R Meyerson, PhD ((415) 306-6333, LMeyerson@venturistherapeutics.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Number of participants with adverse events as a measure of safety and tolerability of i.m. injected Cardio Vascu Grow TM, a recombinant Human Fibroblast Growth Factor-1 (FGF-1-141) (time frame: From enrollment through study completion, an average of 12 weeks). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Aug 2026.